Elevated serum uric acid (SUA) level, i.e., hyperuricaemia, is independently associated with all-cause mortality as well as with several cause-specific types of mortality [1–9]. It has been reasonably speculated that treating asymptomatic hyperuricaemia (elevated SUA without a history of gout attacks) could be beneficial in reducing mortality. However, current guidelines do not generally recommend treatment of asymptomatic hyperuricaemia since there is a lack of sufficient data supporting a favourable benefit-to-risk ratio of treating hyperuricaemia [10–12].
